Pfizer Pflash: A Spotlight on *Clostridioides difficile* (*C. diff*) Vaccine Development

Pfizer
Research & Development



Presentation intended for
the investment community

Forward-Looking Statements and Other Notices

Our discussions during this presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We include forward-looking statements about, among other topics, Pfizer's *Clostridioides difficile (C. difficile)* vaccine candidates, including their potential benefits, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether and when Pfizer will pursue potential development of a *C. difficile* vaccine(s) and whether and when such development would be successful; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any biologics license applications may be filed for the *C. difficile* vaccine candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether the *C. difficile* vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of the *C. difficile* vaccine candidates; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding the *C. difficile* vaccine candidates and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer's business, operations and financial results; and competitive developments. Such statements are forward-looking and are estimates that are subject to change and subject to, among other risks, assumptions and uncertainties, clinical trial, regulatory and commercial success, demand, availability of supply, and competitive and market dynamics.

These statements may be affected by underlying assumptions that may prove inaccurate or incomplete, and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements. Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in Pfizer's subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Potential risks and uncertainties also include global economic and/or geopolitical instability, foreign exchange rate fluctuations and inflationary pressures and the uncertainties regarding the impact of COVID-19. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.

Today's discussions and presentation are intended for the investor community only; they are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. Definitive conclusions cannot be drawn from cross-trial comparisons or anticipated data as they may be confounded by various factors and should be interpreted with caution.

Pfizer Research & Development

Today's Speakers

Hosted by

Francesca DeMartino
Chief Investor Relations Officer

Annaliesa Anderson
Head, Vaccine Research and Development

Alejandra Gurtman
Senior Vice President, Vaccine Clinical Research and Development

Julie Skinner
Vice President, Bacterial Vaccines and Technology

Pfizer Research & Development

Executing on Three Key Pillars in Vaccine Research & Development

Targeting emerging health threats to drive potential long-term growth in viral and bacterial indications

ENHANCE and Augment Core Franchises

- Prevnar 20® Pneumococcal 20-valent Conjugate Vaccine
- COMIRNATY® (COVID-19 Vaccine, mRNA)
- ABRYSVO® Respiratory Syncytial Virus Vaccine

EXECUTE on Mid/Late-Stage Pipeline Portfolio

- *C. difficile* — Phase 2
- Lyme Disease — Phase 3
- Group B Streptococcus — Phase 2
- COVID-19 / Flu Combo — Phase 1/2

GROW Our Pipeline

Preclinical Programs Targeting Bacterial and Viral Pathogens

Pfizer Research & Development

C. difficile: Common & Potentially Fatal Healthcare Associated Infection

Individuals are 7-10 times more likely to contract *C. difficile* while on antibiotics or during following month[1]

Overview of *C. difficile* Infection (CDI) Cascade



Normal gut flora may be altered by antibiotics with other risk factors including age & recent hospital stay

C. difficile flourishes in colon, releasing toxins A & B and causing mucosal damage

Results in fever, abdominal pain, diarrhea, colitis and / or life-threatening complications

Pfizer Research & Development

1. U.S. Centers for Disease Control and Prevention: "About C. diff"; Figure adapted from: McCollum & Rodriguez, Clin Gastroenterol Hepatol. 2012 Jun;10(6):581-92.

C. difficile Infection (CDI) is a Pressing Public Health Threat



Estimated to cause nearly

500K

annual infections in the U.S.[1]

One in eleven

people over 65 diagnosed with healthcare associated *C. diff* infection die within one month[1]

~$5-6B

Estimated annual U.S. healthcare costs[2-4]

No Vaccine

currently available to prevent primary or recurrent *C. difficile* infection

Pfizer Research & Development

1. U.S. Centers for Disease Control and Prevention: "About C. diff"; 2. Zhang et al. BMC Infect Dis. 2016 Aug 25;16(1):447; 3. Desai et al. BMC Infect Dis. 2016 Jun 18:16:303.4. Gupta and Ananthakrishnan Therap Adv Gastroenterol. 2021 May 30;14:17562848211018654; ***C. diff:*** *C. difficile*

First-Generation *C. difficile* Vaccine Candidate Phase 3 Study

Phase 3 CLOVER study had potential to establish regulatory precedent | Began 1Q'17 with data announced in 1Q'22



Primary *C. diff* Infection (CDI) Case Definition Used for Study was Determined in Conjunction with Experts & Regulators

Primary Endpoint was Not Met | Secondary Endpoints & Additional Analyses Showed Signals of Efficacy

Pfizer Research & Development

***C. diff*:** C. difficile; **CDI:** *C. difficile* infection; 1. Confirmed via a central laboratory as *C. difficile* Toxin B (TcdB)-positive via polymerase chain reaction (PCR) and free *C. difficile* toxin-positive via automated proprietary cell cytotoxic neutralization assay

Vaccination Reduced Symptom Duration & Medically Attended *C. diff*

First-generation Phase 3 data demonstrated potential of vaccine candidate to reduce *C. diff* associated healthcare burden

100% Vaccine Efficacy Against Medically Attended *C. diff* Infection and *C. diff* Infection Requiring Antibiotic Intervention

Endpoint	# Meeting Endpoint[1,2]		Vaccine Efficacy (Confidence Interval)[1,2]
	Placebo	Active	
First Episode of *C. diff* Infection (CDI)†	25	17	**31%** (−38.7 to 66.6)
First Episode of CDI that Required Medical Attention‡	11	0	**100%** (59.6 to 100.0)
First Episode of CDI with Antibiotic Use‡	10	0	**100%** (54.8 to 100.0)

†Primary endpoint; the 2-sided 96.4% confidence interval (CI) was derived using the Clopper–Pearson method adjusted for surveillance time. ---- ‡Post hoc endpoint; the 2-sided nominal 95% CI was derived using the Clopper–Pearson method adjusted for surveillance time

75% Reduction in Median *C. diff* Infection (CDI) Duration



*2-sided nominal $p = 0.02$

Pfizer Research & Development

***C. diff*:** C. difficile; **Gen:** Generation. 1. Donskey et al. Clin Infect Dis. 2024 Aug 24:ciae410. doi: 10.1093/cid/ciae410; 2. Results are from the per-protocol 3 population; the per-protocol 3 population included all randomized participants who received doses 1, 2, and 3 of the study intervention to which they were randomized and had no major protocol violations up to and including 14 days after dose 3. 3. Among the 17 active and 24 placebo recipients with first primary CDI episode ≥14 days post-dose 3.

Updated Formulation *C. diff* Vaccine Candidate in Phase 2

Advanced to Phase 2 earlier this year based on encouraging safety and immunogenicity in Phase 1

First-Generation *C. difficile* Vaccine Candidate

Antigen	Antigen	Dosing Regimen
Modified *C. diff* Toxin A	Modified *C. diff* Toxin B	3 Doses Over 6 Months

Exploring Updated Formulations, Dosing Regimens and Potential Phase 3 Trial Design with Next-Gen Program

Formulations

Evaluated three updated formulations including adjuvants in Phase 1

Preferred formulation now in Phase 2

Dosing Regimen

Exploring potential of **two-dose regimens** in Phase 2

Potential Phase 3 Trial Design

Design / endpoints for a potential future Phase 3 study to be informed by past and upcoming data and regulatory interactions

Pfizer Research & Development

***C. diff*:** C. difficile; **Gen:** Generation

Summary: *C. difficile* Vaccine Program

C. diff is a Pressing Public Health Threat with No Approved Vaccine

One in 11 people over age 65 diagnosed with a healthcare associated CDI die within one month[1]



First-Generation Candidate Demonstrated Potential to Reduce *C. diff* Associated Healthcare Burden in Phase 3

Encouraging Safety & Immunogenicity with Updated Formulation in Phase 1

Phase 2 Trial of Updated Formulation Ongoing

Pfizer Research & Development

C. diff: *C. difficile;* **CDI:** *C. diff* Infection; 1. U.S. Centers for Disease Control and Prevention: "About *C. diff*" https://www.cdc.gov/c-diff/about/?CDC_AAref_Val=https://www.cdc.gov/cdiff/risk.html

Q&A Session

Moderated by

Francesca DeMartino
Chief Investor Relations Officer

Annaliesa Anderson
Head, Vaccine Research and Development

Alejandra Gurtman
Senior Vice President, Vaccine Clinical Research and Development

Julie Skinner
Vice President, Bacterial Vaccines and Technology

Pfizer Research & Development